Skottman Heli, Narkilahti Susanna, Hovatta Outi
REGEA, Institute for Regenerative Medicine, University of Tampere and Tampere University Hospital, Biokatu 12, 33520 Tampere, Finland.
Regen Med. 2007 May;2(3):265-73. doi: 10.2217/17460751.2.3.265.
Since the establishment of the first human embryonic stem cell (hESC) lines, several groups have described the derivation and culture of hESC lines in various culture conditions. In this review, we describe how hESC lines have been derived from the inner cell mass of blastocysts or morula-stage embryos and the culture conditions used. In order to be used for therapeutic purposes, the pluripotent hESC lines must be established and propagated according to good manufacturing practice quality requirements. In addition, any use of animal-derived components should be avoided to gain safer hESC lines for clinical purposes. Here, we will describe the development in derivation and chemically defined culturing conditions of hESC towards good manufacturing practice and discuss the future challenges for hESCs in clinical use. Similarly, we discuss the challenges and future directions in optimization of standard culture conditions of hESCs for research purposes.
自首批人类胚胎干细胞（hESC）系建立以来，多个研究团队描述了在不同培养条件下hESC系的衍生和培养方法。在本综述中，我们阐述了hESC系是如何从囊胚或桑葚胚阶段胚胎的内细胞团衍生而来的，以及所使用的培养条件。为了用于治疗目的，必须按照良好生产规范的质量要求来建立和扩增多能性hESC系。此外，应避免使用任何动物源性成分，以便获得更安全的用于临床的hESC系。在此，我们将描述hESC在衍生和化学限定培养条件方面朝着良好生产规范发展的情况，并讨论hESC在临床应用中的未来挑战。同样，我们也会讨论为了研究目的而优化hESC标准培养条件时所面临的挑战和未来方向。
